IL-12 “TAVO”
Intratumoral
Cancer Immunotherapy
Cancer Immunotherapy
Tavokinogene Telseplasmid “TAVO”
Taking the fight directly to the tumor
Through the intratumoral administration of IL-12, our lead product candidate, TAVO, may stimulate a safe but powerful systemic immune response leading to an innovative and potentially transformative therapy option for the treatment of cancer.
Clinical trials of today may power
the medical advances of tomorrow.
Learn more about our current clinical trials:
Arming the Immune System to Fight Cancer
Clinical Pipeline
Our core technology platform continues to advance through clinical trials for various cancers.
Technology
The Intratumoral IL-12 platform is designed to boost the immune system to recognize and attack tumors.
Collaborators
OncoSec continues to establish relationships with industry leaders to further advance our research.